Burgdorf - Ypsomed (SIX: YPSN) is building a new production hall in Schwerin and creating 60 new jobs in the process. The company held the groundbreaking ceremony last Friday thus signaling the start of the construction for the 3300 square meters of additional production space, plus a further 1600 square meters for warehouse capacity and logistics. Digging work is scheduled to begin in June. The plant is expected to be operational following a construction phase of one year. The expansion will allow Ypsomed's site in Schwerin to produce more than 250 million infusion sets, pens and autoinjectors per year going forward.
////
We have the optimal conditions in Schwerin to increase the size of our plant and are already planning further investments. Our task is to ensure that we can adapt our production capacities to the huge demand in good time
explains Simon Michel, CEO of Ypsomed. The initial aim of the production expansion is to satisfy the increasing demand for autoinjectors. This is due to the trend for liquid biotechnologically produced medicinal products, many of which can no longer be swallowed and instead need to be injected. In addition, there is also a trend towards self-treatment. More and more chronic diseases can be treated by patients themselves at home with autoinjectors. These developments are leading to rapid growth in the autoinjector market.
Ypsomed Produktion GmbH currently employs around 150 employees in Schwerin. The production facility operates in shifts manufacturing autoinjectors, pens and infusion sets for insulin pumps. Sixty further positions will be created as part of the production expansion.
The ceremony was attended by representatives from politics and business, including Reinhard Meyer, Mecklenburg-Vorpommern's Minister of Economics, Infrastructure, Tourism and Labour. The construction project will be carried out by several regional companies. These include Rostock-based company Goldbeck, who will handle construction of the building itself, and Dr. Diestel GmbH, who will be responsible for the air-conditioning system.
Facts and figures on the production expansion in Schwerin
Current size of production facility: 13,500 m2 of production capacity, 4,250 m2 of storage space
Production capacity to be extended by around 3,300 m2, 1,600 m2 of additional space for warehouse and logistics
Investment of around 20 million euros
Construction time of 12 months, handover to production scheduled for summer 2024
Press release as PDF and images
Ypsomed expands production in Schwerin(90.7 KiB)
Groundbreaking ceremony for new Ypsomed production hall in Schwerin 2023(4.9 MiB)
Ypsomed Holding AG published this content on 09 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 May 2023 05:09:01 UTC.
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.